The Effect of General Anesthesia and Thoracic Paravertebral Block combined General Anesthesia on Immune Function of Patients with Breast Cancer in Perioperative Period of Radical Mastectomy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-14004573

Enrollment

Unknown

Registered

2014-04-27

Start date

2014-04-27

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

General Anesthesia:General Anesthesia: Diprivan TCI (2-4ug/ml), sufentanil (1ug/kg) and Vecuronium (1mg/kg) are used in induction period, Diprivan TCI (2ug/ml) is used in maintenance period.

horacic Paravertebral Block combined General Anest:horacic Paravertebral Block Thoracic Paravertebral Block Combined General Anesthesia: 0.5% Levobupivacaine (20mL) is injected from T3-4 Thoracic para

Diprivan TCI (4-6ug/ml), sufentanil (0.6-0.8ug/kg) and Vecuronium (1mg/kg) are used in induction period, Diprivan TCI (2-4ug/ml) is used in maintenance period.

Eligibility

Sex/Gender

Female

Age

25 Years to 65 Years

Inclusion criteria

Inclusion criteria: Breast cancer patient without treatment, female, aged 25-65 yeears old, without other diseases, such as endocrine diseases, immune function disorders and etc., and have not carried out radiotherapy and chemotherapy.

Exclusion criteria

Exclusion criteria: Complicated with other disease, have accepted surgiry, radiotherapy and chemotherapy.

Design outcomes

Primary

Measure	Time frame
peripheral lymphocyt;	—

Countries

China

Contacts

Public ContactLi Xiaoxiao

Xiangya 3rd Hosiptital, Central South University

lxx0118@126.com+86 13548942180

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026